Ovarian cancer: opportunity for targeted therapy.

J Oncol · 2012 · PMC3253450 · PMID 22235203

Europe PMC DOI

hedged sentence

0.0022

closest p · 0.0× alpha

0.0022

boldest claim

The sentences

showed a trendP = 0.0022actually significant

Phase III studies involving chemotherapy with or without bevacizumab presented during the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) showed a trend toward an overall survival benefit in patients treated with bevacizumab in addition to chemotherapy in the first line setting with HR = 0.64 P = 0.0022 in those with poor prognosis disease (ICON7).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.